|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,990,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Bicycle Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Bicycles are a therapeutic modality combining the pharmacology associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Co. is evaluating BT5528, a Bicycle Toxin Conjugate (BTC) targeting Ephrin type-A receptor 2, BT8009, a BTC targeting Nectin-4, and BT7480, a Bicycle tumor-targeted immune cell agonist® targeting Nectin-4 and agonizing CD137. In addition, BT1718, a BTC that is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
7,268 |
14,490 |
37,488 |
61,094 |
Total Sell Value |
$142,744 |
$314,362 |
$724,634 |
$1,369,761 |
Total People Sold |
7 |
7 |
7 |
9 |
Total Sell Transactions |
7 |
14 |
26 |
45 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Lee Kevin |
Chief Executive Officer |
|
2021-01-20 |
4 |
AS |
$31.33 |
$37,779 |
D/D |
(1,185) |
258,900 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-01-19 |
4 |
AS |
$30.00 |
$450,000 |
D/D |
(15,000) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-01-19 |
4 |
OE |
$1.59 |
$23,850 |
D/D |
15,000 |
15,000 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-01-19 |
4 |
AS |
$29.14 |
$146,290 |
D/D |
(5,000) |
260,085 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-01-15 |
4 |
AS |
$27.01 |
$135,050 |
D/D |
(5,000) |
265,085 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-01-14 |
4 |
AS |
$25.00 |
$250,000 |
D/D |
(10,000) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2021-01-14 |
4 |
OE |
$1.60 |
$16,000 |
D/D |
10,000 |
10,000 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2021-01-14 |
4 |
AS |
$25.00 |
$125,000 |
D/D |
(5,000) |
270,085 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2020-12-01 |
4 |
AS |
$22.50 |
$168,750 |
D/D |
(7,500) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2020-12-01 |
4 |
OE |
$1.56 |
$11,700 |
D/D |
7,500 |
7,500 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2020-11-27 |
4 |
AS |
$20.00 |
$10,600 |
D/D |
(530) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2020-11-27 |
4 |
OE |
$1.56 |
$827 |
D/D |
530 |
530 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2020-11-25 |
4 |
AS |
$20.07 |
$196,305 |
D/D |
(9,781) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2020-11-25 |
4 |
OE |
$1.56 |
$15,258 |
D/D |
9,781 |
9,781 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2020-11-23 |
4 |
AS |
$19.82 |
$340,805 |
D/D |
(17,189) |
0 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2020-11-23 |
4 |
OE |
$1.56 |
$26,815 |
D/D |
17,189 |
17,189 |
|
- |
|
Glaxosmithkline Plc |
10% Owner |
|
2020-07-15 |
4 |
S |
$19.25 |
$61,045 |
I/I |
(3,147) |
1,910,531 |
|
- |
|
Glaxosmithkline Plc |
10% Owner |
|
2020-07-14 |
4 |
S |
$19.27 |
$30,781 |
I/I |
(1,597) |
1,913,678 |
|
- |
|
Winter Gregory Paul |
Director |
|
2020-04-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
71,450 |
163,927 |
|
- |
|
Cambridge Innovation Capital (jersey) Ltd |
10% Owner |
|
2019-05-29 |
4 |
B |
$14.00 |
$4,400,004 |
D/D |
314,286 |
1,751,437 |
2.45 |
- |
|
Aquila Investments Iv |
10% Owner |
|
2019-05-28 |
4 |
B |
$14.00 |
$5,100,004 |
I/I |
364,286 |
1,957,961 |
1.5 |
- |
|
Aquila Investments Iv |
10% Owner |
|
2019-05-28 |
4 |
OE |
$0.00 |
$0 |
I/I |
139,264 |
1,593,675 |
|
- |
|
Aquila Investments Iv |
10% Owner |
|
2019-05-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,454,411 |
1,454,411 |
|
- |
|
Ng Carolyn |
Director |
|
2019-05-28 |
4/A |
A |
$0.00 |
$0 |
I/I |
1,479,500 |
1,427,151 |
|
- |
|
Ng Carolyn |
Director |
|
2019-05-28 |
4/A |
OE |
$0.00 |
$0 |
I/I |
141,668 |
1,207,410 |
|
- |
|
226 Records found
|
|
Page 8 of 10 |
|
|